Advertisement
Advertisement
OTLK
Outlook Therapeutics, Inc. Common Stock
1.02
USDSponsored
+0.05
+4.88%
Aug 07, 15:59 UTC -4
Closed
After-Market
1.02
0.00
+0.49%
OTLK Earnings Reports
Positive Surprise Ratio
OTLK beat 18 of 37 last estimates.
49%
Next Report
In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
$5.41M
/-$0.09
Implied change from Q2 26 (Revenue/ EPS)
+4123.44%
/-43.75%
Implied change from Q3 25 (Revenue/ EPS)
+259.20%
/-83.64%
Outlook Therapeutics, Inc. Common Stock earnings per share and revenue
On May 15, 2026, OTLK reported earnings of -0.16 USD per share (EPS) for Q2 26, missing the estimate of -0.12 USD, resulting in a -30.72% surprise. Revenue reached 128.00 thousand, compared to an expected 4.49 million, with a -97.15% difference. The market reacted with a +0.48% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 5.41 million USD, implying an decrease of -43.75% EPS, and increase of 4123.44% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Outlook Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Outlook Therapeutics, Inc. Common Stock reported EPS of -$0.16, missing estimates by -30.72%, and revenue of $128.00K, -97.15% below expectations.
How did the market react to Outlook Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.48%, changed from $0.23 before the earnings release to $0.23 the day after.
When is Outlook Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Outlook Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Outlook Therapeutics, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $5.41M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement